OBJECTIVES: A decreased ability to degrade neutrophil extracellular traps (NETs) is seen in a subgroup of patients with systemic lupus erythematosus (SLE) and correlates with the presence of autoantibodies. Antiphospholipid syndrome (APS) can develop secondary to SLE or as a primary disease. In the current study we investigated the ability of sera from patients with APS to degrade NETs. The presence of antibodies against NETs and neutrophil remnants were also determined in the same patients. METHODS: In the study, 106 patients with APS (73 primary and 33 secondary), 76 patients with systemic sclerosis (SSc) and 77 healthy donors as control samples were included. NETs generated from neutrophils isolated from healthy volunteers were incubated with patient sera, followed by measurement of degraded NETs or deposited IgG. RESULTS: Sera of APS patients had a decreased ability to degrade NETs compared to healthy controls, with no difference between primary and secondary APS. Sera from SSc patients did not differ significantly from healthy controls in the ability to degrade NETs. A decreased degradation of NETs correlated weakly to increased levels of antibodies against NETs/neutrophil remnants in patients with primary APS, but stronger in patients with secondary APS. CONCLUSIONS: The ability to degrade NETs is decreased in a subgroup of patients with APS and is associated with antibodies against NETs and specific clinical manifestations in those patients.
OBJECTIVES: A decreased ability to degrade neutrophil extracellular traps (NETs) is seen in a subgroup of patients with systemic lupus erythematosus (SLE) and correlates with the presence of autoantibodies. Antiphospholipid syndrome (APS) can develop secondary to SLE or as a primary disease. In the current study we investigated the ability of sera from patients with APS to degrade NETs. The presence of antibodies against NETs and neutrophil remnants were also determined in the same patients. METHODS: In the study, 106 patients with APS (73 primary and 33 secondary), 76 patients with systemic sclerosis (SSc) and 77 healthy donors as control samples were included. NETs generated from neutrophils isolated from healthy volunteers were incubated with patient sera, followed by measurement of degraded NETs or deposited IgG. RESULTS: Sera of APSpatients had a decreased ability to degrade NETs compared to healthy controls, with no difference between primary and secondary APS. Sera from SSc patients did not differ significantly from healthy controls in the ability to degrade NETs. A decreased degradation of NETs correlated weakly to increased levels of antibodies against NETs/neutrophil remnants in patients with primary APS, but stronger in patients with secondary APS. CONCLUSIONS: The ability to degrade NETs is decreased in a subgroup of patients with APS and is associated with antibodies against NETs and specific clinical manifestations in those patients.
Authors: Robert C Grenn; Srilakshmi Yalavarthi; Alex A Gandhi; Nayef M Kazzaz; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Antonio R Cabral; W Joseph McCune; Paula L Bockenstedt; Jason S Knight Journal: Ann Rheum Dis Date: 2016-07-18 Impact factor: 19.103
Authors: Sebastian Boeltz; Poorya Amini; Hans-Joachim Anders; Felipe Andrade; Rostyslav Bilyy; Simon Chatfield; Iwona Cichon; Danielle M Clancy; Jyaysi Desai; Tetiana Dumych; Nishant Dwivedi; Rachael Ann Gordon; Jonas Hahn; Andrés Hidalgo; Markus H Hoffmann; Mariana J Kaplan; Jason S Knight; Elzbieta Kolaczkowska; Paul Kubes; Moritz Leppkes; Angelo A Manfredi; Seamus J Martin; Christian Maueröder; Norma Maugeri; Ioannis Mitroulis; Luis E Munoz; Daigo Nakazawa; Indira Neeli; Victor Nizet; Elmar Pieterse; Marko Z Radic; Christiane Reinwald; Konstantinos Ritis; Patrizia Rovere-Querini; Michal Santocki; Christine Schauer; Georg Schett; Mark Jay Shlomchik; Hans-Uwe Simon; Panagiotis Skendros; Darko Stojkov; Peter Vandenabeele; Tom Vanden Berghe; Johan van der Vlag; Ljubomir Vitkov; Maren von Köckritz-Blickwede; Shida Yousefi; Alexander Zarbock; Martin Herrmann Journal: Cell Death Differ Date: 2019-01-08 Impact factor: 15.828
Authors: Kandace Gollomp; Minna Kim; Ian Johnston; Vincent Hayes; John Welsh; Gowthami M Arepally; Mark Kahn; Michele P Lambert; Adam Cuker; Douglas B Cines; Lubica Rauova; M Anna Kowalska; Mortimer Poncz Journal: JCI Insight Date: 2018-09-20
Authors: He Meng; Srilakshmi Yalavarthi; Yogendra Kanthi; Levi F Mazza; Megan A Elfline; Catherine E Luke; David J Pinsky; Peter K Henke; Jason S Knight Journal: Arthritis Rheumatol Date: 2017-03 Impact factor: 10.995